SAN FRANCISCO (MarketWatch) -- Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corp. will pay $72.5 million to resolve allegations that Novartis /quotes/comstock/13*!nvs/quotes/nls/nvs (NVS 49.82, -0.72, -1.42%) marketed TOBI, a cystic fibrosis drug, for unapproved uses, the Department of Justice said Tuesday. This in turn led to the submission of false claims to federal health care programs. "Pharmaceutical companies must not promote their drugs for uses that have not been proven to be safe and effective," said Tony West, assistant attorney general for the DOJ's civil division.
via marketwatch.com
No comments:
Post a Comment